Apyx Medical Corporation

NASDAQ:APYX

Medical - Devices

Healthcare
$2.49 -1.90%

-$0.08 today

Market cap
$104.89M
Beta
1.39
P/E (TTM)
-19.0
EPS (TTM)
-$0.22
52W Low $1.59High $5.08

Volume 0.19M

Average 0.18M

APYX Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Apyx Medical CorporationNASDAQ: APYX

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $83K rose 232.0% year over year, ahead of the +42.3% change in trailing-twelve-month financing cash flow. Sequentially, it fell 99.1% from the prior quarter. Over 3 fiscal years it compounded at +253.4% a year.

Context

  • Financing cash flow amounted to 18.1% of revenue in FY2025, up 4.1 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +232.0% holds above the trailing-twelve-month pace of +42.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$83K-99.1% QoQ
Last fiscal yearDec 2025
$9.58M+42.0% YoY
LTMMar 2026
$9.64M+42.3% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+232.0%——
1 year+42.0%——
3-year CAGR+253.4%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
9.58M USD
Year-over-year change
+42.0%
4-year CAGR
+347.0%

Financing Cash Flow vs competitors

How APYX compares with its peers on the latest reported figures

  • APYX's LTM Mar 2026 financing cash flow of $9.64M is the 7th largest of the 8 companies compared; the peer median is $18.76M.
  • Its year-over-year change of +42.3% is the 4th highest of 8, against a peer median of +8.7%.
  • Financing cash flow amounts to 17.2% of revenue for APYX, versus a peer median of 41.6%.
APYX Competitors Peer median
Financing Cash Flow for APYX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$49.08M +8.7%+182.8%955.9%
VANIVivani Medical, Inc.LTM Mar 2026$33.16M +538.4%-28.4%—
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$21.93M -319.8%—18.0%
RCELAVITA Medical, Inc.LTM Mar 2026$20.67M +538.0%+155.1%28.6%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$18.76M +4324.8%+205.6%54.6%
PDEXPro-Dex, Inc.LTM Mar 2026$11.23M -1124.4%-28.2%15.0%
APYXApyx Medical CorporationLTM Mar 2026$9.64M +42.3%+253.4%17.2%
SERASera Prognostics, Inc.LTM Mar 2026$504K -99.1%+2110.8%884.2%
Peer median (excluding APYX) $18.76M+8.7%+168.9%41.6%

Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(15.2M)(23.28M)(18.85M)(23.56M)(11.11M)
Depreciation & Amortization903K890K692K599K655K
Deferred Income Tax00000
Stock-Based Compensation5.09M6.7M5.11M4.01M2M
Change in Working Capital(1.84M)(5.22M)5.54M(1.25M)(1.59M)
Accounts Receivables(4.9M)1.92M3.97M(2.04M)(1.32M)
Inventory(2.86M)(5.57M)1.46M2.26M(1.07M)
Accounts Payables1.15M67K25K(63K)355K
Other Working Capital4.76M(1.63M)88K(1.41M)446K
Other Non-Cash Items603K628K2.25M2.15M2.04M
Operating Cash Flow(10.45M)(20.28M)(5.25M)(18.05M)(8M)
Capital Expenditures(723K)(1.01M)(533K)(722K)(1.11M)
Acquisitions (Net)195K07.41M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(195K)0(147K)00
Investing Cash Flow(723K)(1.01M)6.73M(722K)(1.11M)
Debt Repayment(238K)(148K)35.04M(20K)(20K)
Common Stock Issued67K365K2.72M7M9.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities195K0(5.59M)(235K)60K
Financing Cash Flow24K217K32.17M6.75M9.58M
Effect of Forex Changes103K395K(191K)113K(466K)
Net Change in Cash(11.05M)(20.68M)33.46M(11.91M)(1K)
Free Cash Flow(11.17M)(21.29M)(5.78M)(18.77M)(9.12M)

Apyx Medical Corporation

NASDAQ:APYX

Intrinsic Alpha fair value

Locked

Current Price

$2.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.